Rindopepimut (Rintega®, Celldex Therapeutics, Inc., Phillipsburg, NJ, USA), a 14-mer injectable peptide vaccine against EGFRvIII, was projected to activate CD4+ and CD8+ T cells against malignant brain tumor cells (Figure 4). This evidence concerns the gene CD4 and brain neoplasm.